Biocorrx (OTCMKTS:BICX – Get Free Report) and IceCure Medical (NASDAQ:ICCM – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, earnings, profitability and institutional ownership.
Profitability
This table compares Biocorrx and IceCure Medical’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Biocorrx | N/A | N/A | -96.39% |
| IceCure Medical | -445.61% | -221.04% | -118.89% |
Institutional and Insider Ownership
0.6% of IceCure Medical shares are owned by institutional investors. 21.4% of Biocorrx shares are owned by company insiders. Comparatively, 2.4% of IceCure Medical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Volatility and Risk
Analyst Ratings
This is a summary of current recommendations for Biocorrx and IceCure Medical, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Biocorrx | 0 | 1 | 0 | 0 | 2.00 |
| IceCure Medical | 1 | 1 | 1 | 0 | 2.00 |
IceCure Medical has a consensus target price of $2.64, suggesting a potential upside of 839.39%. Given IceCure Medical’s higher possible upside, analysts clearly believe IceCure Medical is more favorable than Biocorrx.
Earnings and Valuation
This table compares Biocorrx and IceCure Medical”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Biocorrx | $10,000.00 | 1,056.00 | -$5.11 million | ($0.32) | -1.25 |
| IceCure Medical | $3.38 million | 6.07 | -$15.06 million | ($0.24) | -1.17 |
Biocorrx has higher earnings, but lower revenue than IceCure Medical. Biocorrx is trading at a lower price-to-earnings ratio than IceCure Medical, indicating that it is currently the more affordable of the two stocks.
Summary
Biocorrx beats IceCure Medical on 7 of the 13 factors compared between the two stocks.
About Biocorrx
BioCorRx Inc., through its subsidiaries, develops and provides treatment programs for substance abuse and related disorders in the United States. It distributes and licenses BioCorRx recovery program, a non-addictive and medication-assisted treatment program that includes a counseling program coupled with its proprietary naltrexone implant; and distributes UnCraveRx weight loss management program, a medically assisted weight management program to reduce food cravings combined with on-demand virtual lifestyle support, fitness, and nutrition. The company is also developing BICX101, an injectable naltrexone product; and BICX104, an implantable naltrexone implant for the treatment of opioid addiction and alcoholism. It distributes its program to healthcare providers, independent licensed clinics, and licensed healthcare professionals. The company was formerly known as Fresh Start Private Management, Inc. and changed its name to BioCorRx Inc. in January 2014. BioCorRx Inc. is based in Anaheim, California.
About IceCure Medical
IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MultiSense, a multi probe system for the treatment of multiple and larger tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.
Receive News & Ratings for Biocorrx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biocorrx and related companies with MarketBeat.com's FREE daily email newsletter.
